Multicenter Prospective Cohort Study of Hodgkin Lymphoma

ational Cancer Center0 个研究点目标入组 350 人开始时间: 待定最近更新: 2019年11月5日

适应症

试验速览

暂无简介。

•Never treated, newly diagnosed classical Hodgkin lymphoma patient by pathologic examination
•- age 18 and older
•- ECOG 0-2
•- At least one measurable lesion (2cm or more on conventional CT or 1cm or more on spiral CT)
•- At least one identifiable uptake of nodes or extranodal lesion on FDG PET-CT
•- Adequate renal function (serum creatinine =2.5mg/dL, creatinine clearance = 50mL/min)
•- Adequate liver function (AST and ALT = 3 times of upper normal limit, bilirubin = 1.5 times of upper normal limit, alkaline
•phosphatase = 5 times of upper normal limit)
•- Adequate bone marrow function (ANC = 1,500/uL, platelet =75,000/uL, hemoglobin = 9.0g/dL)
•- Adequate cardiopulmonary function
•- Voluntary achieved informed consent approved by institutional review board

•- Not correspond to inclusion criteria
•- Malignant tumor within 5 years of enrollment except skin basal cell carcinoma and cervix carcinoma in situ.
•- Clinically significant medical status (uncontrolled cardiac disease, history of myocardial infarction within 6 months of enrollment, uncontrolled pulmonary disease, significant neurological or psychological disease including dementia and epilepsy, uncontrolled active infection)
•- Pregnancy or breastfeeding, childbearing-age female without adequate contraception
•- Confirmed allergic response to drugs of present study
•- Not consent to present study

发起方

ational Cancer Center